METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

• US 20160022898A1
• Filed: 10/01/2015
• Published: 01/28/2016
• Est. Priority Date: 12/13/2005
• Status: Active Grant

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: LARM, OLLE, BERGSTROM, TOMAS
• Granted Patent: US 9,764,077 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/203 Bacteria
• CPC Class Codes: A61M 2202/206 Viruses
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Claims

1. A method for treating a subject in need thereof, by extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein, said method comprising:

a) contacting said subject'"'"'s whole blood with heparin immobilized on a solid substrate, wherein said heparin is covalently linked by end-point attachment under conditions allowing binding of said pathogenic microbe, said inflammatory cell or said inflammatory protein to the heparin;

b) separating the whole blood from the solid substrate; and

c) recovering said whole blood containing a reduced amount of said pathogenic microbe, said inflammatory cell or said inflammatory protein.

2. The method of claim 1, further comprising:

d) reintroducing into said subject said whole blood containing a reduced amount of said pathogenic microbe, said inflammatory cell or said inflammatory protein.

3. The method of claim 1, wherein said solid substrate comprises microparticles.

4. The method of claim 1, wherein said solid substrate comprises fibers.

5. The method of claim 1, wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.

6. The method of claim 1, wherein said pathogenic microbe is selected from the group consisting of bacteria, viruses and parasites.

7. The method of claim 6, wherein said pathogenic microbe is a virus.

8. The method of claim 7, wherein said virus is selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, Influenza A virus, cytomegalovirus and human immunodeficiency virus.

9. The method of claim 8, wherein said virus is selected from the group consisting of herpes simplex virus type 1 and herpes simplex virus type 2.

10. The method of claim 6, wherein said pathogenic microbe is a bacterium.

11. The method of claim 10, wherein said bacterium is selected from the group consisting of Helicobacter pylori, Streptococcus sanguis, Streptococcus mutans, Escherichia coli, Pseudomonas aureginosa and Mycobacterium tuberculosis.

12. The method of claim 11, wherein said bacterium is Helicobacter pylori.

13. The method of claim 6, wherein said pathogenic microbe is a parasite.

14. The method of claim 13, wherein said parasite is selected from the group consisting of Plasmodium falciparum and Trypanosoma cruzi.

15. The method of claim 1, wherein said inflammatory cell is selected from the group consisting of inflammatory lymphocytes and inflammatory macrophages.

16. The method of claim 15, wherein said inflammatory protein is a pro-inflammatory cytokine.

17. The method of claim 16, wherein said pro-inflammatory cytokine is selected from the group consisting of tumor necrosis factor alpha (TNF-α

), tumor necrosis factor beta (TNF-β

), interleukin-1 (IL-1), and interleukin-6 (IL-6).